TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

OXISTAT

OXICONAZOLE NITRATE
Infectious Disease Approved 1988-12-30
3
Indications
--
Phase 3 Trials
37
Years on Market

Details

Status
Prescription
First Approved
1988-12-30
Routes
TOPICAL
Dosage Forms
CREAM, LOTION

Companies

Active Ingredient: OXICONAZOLE NITRATE

OXISTAT Approval History

Loading approval history...

What OXISTAT Treats

3 indications

OXISTAT is approved for 3 conditions since its original approval in 1988. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Tinea Pedis
  • Tinea Cruris
  • Tinea Corporis
Source: FDA Label

Drugs Similar to OXISTAT

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CLOTIC
CLOTRIMAZOLE
3 shared
CARWIN PHARM ASSOC
Shared indications:
Tinea PedisTinea CrurisTinea Corporis
CLOTRIMAZOLE
CLOTRIMAZOLE
3 shared
GLENMARK PHARMS
Shared indications:
Tinea PedisTinea CrurisTinea Corporis
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE
BETAMETHASONE DIPROPIONATE
3 shared
FOUGERA PHARMS
Shared indications:
Tinea PedisTinea CrurisTinea Corporis
EXELDERM
SULCONAZOLE NITRATE
3 shared
JOURNEY
Shared indications:
Tinea PedisTinea CrurisTinea Corporis
FULVICIN P/G
GRISEOFULVIN, ULTRAMICROSIZE
3 shared
CHARTWELL RX
Shared indications:
Tinea CorporisTinea PedisTinea Cruris
FULVICIN P/G 165
GRISEOFULVIN, ULTRAMICROSIZE
3 shared
CHARTWELL RX
Shared indications:
Tinea CorporisTinea PedisTinea Cruris
FULVICIN-U/F
GRISEOFULVIN, MICROSIZE
3 shared
CHARTWELL RX
Shared indications:
Tinea CorporisTinea PedisTinea Cruris
GRISEOFULVIN
GRISEOFULVIN, MICROSIZE
3 shared
Novartis
Shared indications:
Tinea corporisTinea crurisTinea pedis
LUZU
LULICONAZOLE
3 shared
BAUSCH
Shared indications:
Tinea PedisTinea CrurisTinea Corporis
OXICONAZOLE NITRATE
OXICONAZOLE NITRATE
3 shared
SUN PHARMA CANADA
Shared indications:
Tinea PedisTinea CrurisTinea Corporis
SCLEROSOL
TALC
2 shared
SCIARRA LABS
Shared indications:
Tinea PedisTinea Corporis
STERITALC
TALC
2 shared
NOVATECH SA
Shared indications:
Tinea PedisTinea Corporis
TALC
TALC
2 shared
SCIARRA LABS
Shared indications:
Tinea PedisTinea Corporis
ECOZA
ECONAZOLE NITRATE
1 shared
RESILIA PHARMS
Shared indications:
Tinea Pedis
ERTACZO
SERTACONAZOLE NITRATE
1 shared
LACER PHARMA
Shared indications:
Tinea Pedis
NAFTIFINE HYDROCHLORIDE
NAFTIFINE HYDROCHLORIDE
1 shared
AMNEAL
Shared indications:
Tinea Pedis
NAFTIN
NAFTIFINE HYDROCHLORIDE
1 shared
LEGACY PHARMA
Shared indications:
Tinea Pedis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

OXISTAT FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

OXISTAT Lotion is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ).

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.